June 2013
EpitoGenesis was awarded a Phase I Advanced Technology STTR grant from the National Institutes of Allergy and Infectious Diseases to
June 13, 2013
Menu
News
October 2010
EpitoGenesis enters into an agreement with Children’s Hospital Oakland Research Institute on a collaborative project to develop a vaccine against
October 21, 2010
October 2010
EpitoGenesis, Inc. is awarded an NIH grant to further explore the NIDS technology for HIV vaccines.
October 21, 2010
October 2010
EpitoGenesis begins collaboration with Dr. Julia Hurwitz at St. Jude’s Hospital on an HIV vaccine project and submission of a
October 21, 2010
August 2010
EpitoGenesis Publication: Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.Yu M, Vajdy M.Expert Opin Biol Ther.
August 10, 2010
January 2010
EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses
January 28, 2010
December 2009
EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses
December 8, 2009
May 2009
EpitoGenesis Inc. was awarded a Phase I, Small Business Innovation Research grant from the National Institutes of Health to develop
May 18, 2009
January 2009
EpitoGenesis Inc. filed an application for an SBIR phase I grant for research and development of a mucosal HIV vaccine.
January 11, 2009
December 2008
Moved in Laboratory and office space at 112 La Casa Via, suite 160, Walnut Creek, California, across from John Muir
December 16, 2008